Healthcare
RaySearch Laboratories AB (publ)(RSLBF)
Live Price
Offline$21.33
+0.00% today
Window Change
-11.13%
Window
May 29, 2026 β Jun 18, 2026
- Market Cap
- $6.51B
- Revenue Growth
- +12.8%
- EPS Growth
- +12.0%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars Β· May 29, 2026 β Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RaySearch Laboratories AB (publ) (RSLBF) is a Healthcare stock with a market cap of $6.51B and listed on OTC. The stock last traded around $21.33 and down 11.1% across the available one-year price window (May 29, 2026 β Jun 18, 2026). Baseline metrics include revenue growth of +12.8%, EPS growth of +12.0%, a dividend yield of 0.0%. What stands out right now is revenue +12.8%, EPS +12.0%, free cash flow -40.6% with operating margin 21.6% and ROIC 14.4%. Valuation sits in the middle of the pack at P/E 29.0 and price/sales 5.0. Stock Foundry combines RSLBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+12.8% vs +7.6% peer median
Operating Margin
Above sector median
+21.6% vs +19.4% peer median
P/E
Below sector median
29.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +12.8% and EPS at +12.0%, with operating margin around 21.6%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RSLBF
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
RSLBF Max Drawdown
-11.13%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RSLBF and SPY.
Company Overview
RaySearch Laboratories AB (publ)
Other OTC
RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment worldwide. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, OAR dose reduction, robustness, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information system to support cancer treatment activities. In addition, it offers RayCommand, a treatment control system that is compatible with various hardware models and supports advanced functionalities of treatment machines and software systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights. Further, the company provides training courses related to its products. RaySearch Laboratories AB (publ) is headquartered in Stockholm, Sweden.
- Leadership
- Johan Lof
- IPO Date
- Jun 9, 2015
- Employees
- 416
- Street Address
- SveavΓ€gen 44
- Mailing
- Stockholm, 111 34
- Region
- Stockholm, SE
- Reporting Currency
- USD
- Investor Line
- 46 8 51 05 30 00
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 29.0
- EV/EBITDA
- 15.2
- Price/Sales
- 5.0
- Price/Book
- 6.2
Growth
- Revenue
- +12.8%
- EPS
- +12.0%
- Free Cash Flow
- -40.6%
Profitability
- Gross Margin
- 81.4%
- Operating Margin
- 21.6%
- Net Margin
- 17.2%
- ROE
- 23.6%
- ROIC
- 14.4%
Balance Sheet
- Debt/Equity
- 0.36
- Current Ratio
- 1.79
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.